Compare Dulaglutide (evidence A) and Exenatide (evidence A) on mechanism, clinical status, safety, and dosing.
Dulaglutide (brand name Trulicity) is a once-weekly GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in September 2014 for type 2 diabetes. It is a…
Exenatide is a 39-amino-acid GLP-1 receptor agonist (MW ~4186.6 g/mol) originally derived from exendin-4, a peptide found in the saliva of the Gila monster…
Full profiles: Dulaglutide, Exenatide.